News | November 03, 2023
Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr
Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023
Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023
The company has posted net profit of Rs.115.08 crores for half year ended September 30, 202
Mankind Pharma has reported total income of Rs. 2768.07 crores during the period ended September 30, 2023
Thyrocare Technologies has reported total income of Rs. 150.17 crores during the period ended September 30, 2023
Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023
The inspection of the facility conducted from August 7 to August 11, 2023
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Subscribe To Our Newsletter & Stay Updated
